Comprehension of Information by Biosimilar Disclosure Characteristic
| Biosimilar Disclosure Characteristic | |||||
|---|---|---|---|---|---|
| Kesterin is a Biosimilar + Effective | Kesterin is a Biosimilar + Effective + Same Sources | Kesterin is a Biosimilar + Effective + Same Sources + Dosage and Administration | Names the Reference Drug Mytrozen in Definition | Does Not Name Reference Drug in Definition | |
| Consumers (n = 379) | |||||
| Correctly understood Kesterin has the same safety and efficacy as original | 50 (48.5%) | 44 (48.4%) | 55 (57.3%) | 81 (54.0%) | 68 (48.6%) |
| Correctly understood Kesterin is made from the same types of sources as original | N/A | 56 (61.5%) | 53 (55.2%) | 62 (62.0%) | 47 (54.0%) |
| Correctly understood Kesterin has the same strength and dosage as original | N/A | N/A | N/A | 27 (51.9%) | 22 (50.0%) |
| HCPs (n = 360) | |||||
| Correctly understood Kesterin has the same safety and efficacy as original | 65 (74.7%) | 65 (68.4%) | 70 (72.2%) | 99 (74.4%) | 101 (69.2%) |
| Correctly understood Kesterin is made from the same types of sources as original | N/A | 84 (88.4%) | 77 (79.4%) | 78 (83.9%) | 83 (83.8%) |
| Correctly understood Kesterin has the same strength and dosage as original | N/A | N/A | N/A | 34 (75.6%) | 43 (82.7%) |
Abbreviation: HCPs, Health care providers.
Note: All P-values across for described comparisons were nonsignificant at the Bonferroni adjusted values. Control condition did not receive comprehension questions.
N/A – comprehension item not assessed for given condition.